Deltec Asset Management LLC Makes New $1.51 Million Investment in Illumina, Inc. (NASDAQ:ILMN)

Deltec Asset Management LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 14,500 shares of the life sciences company’s stock, valued at approximately $1,514,000.

Other large investors also recently bought and sold shares of the company. Trivant Custom Portfolio Group LLC increased its holdings in Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after acquiring an additional 125 shares in the last quarter. Versant Capital Management Inc increased its holdings in Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 246 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new position in Illumina during the 4th quarter valued at about $37,000. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 86.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after acquiring an additional 132 shares in the last quarter. Finally, MeadowBrook Investment Advisors LLC purchased a new position in Illumina during the 4th quarter valued at about $42,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 2.1 %

ILMN stock traded up $2.56 during midday trading on Wednesday, reaching $122.28. 2,154,758 shares of the company’s stock traded hands, compared to its average volume of 2,127,941. The company has a market capitalization of $19.48 billion, a P/E ratio of -15.08 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $178.44. The business has a 50-day moving average price of $113.76 and a two-hundred day moving average price of $122.63.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. Illumina’s revenue was down 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.32 earnings per share. Equities research analysts forecast that Illumina, Inc. will post 1.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ILMN shares. Scotiabank dropped their target price on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a report on Monday, May 6th. Barclays upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price target for the company in a report on Wednesday. Evercore ISI lowered their price target on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a report on Tuesday, June 11th. Jefferies Financial Group initiated coverage on shares of Illumina in a report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target for the company. Finally, Robert W. Baird lifted their price target on shares of Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $151.55.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.